ADVANCE Studies Ralinepag (IP receptor agonist)
Ralinepag, extended-release tablets, for oral use
ROUTE OF ADMINISTRATION
NCE / Novel Biologics
Worldwide, subject to out-licenses granted in the People’s Republic of China and certain other Asian territories
Ralinepag is a development-stage product not approved for sale in any jurisdiction.